MID-35

A small experimental peptide. MID-35 has 16 building blocks arranged as a reversed D-peptide to resist breakdown. Developed from MIPE-1686, it interferes with myostatin, a signal limiting skeletal muscle growth. Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice (Animal context · Accessed 2026-09-30)

MID-35 is an experimental myostatin-inhibiting peptide discussed for local muscle growth. Community interest draws on mouse research; these accounts supply no firsthand human result, typical dose or feeling.

Local muscle growth is the attraction. The community comparison places MID-35 beside FLGR-242: published local-muscle experiments versus a marketed systemic-growth story. That comparison explains the interest; it does not establish interchangeable compounds, routes or results.

2022: one locally treated muscle. A single 30 nmol intramuscular administration produced a treated mouse muscle weighing 133% of the opposite saline-treated muscle at day 28. That means roughly 33% heavier, not a 133% gain in a person's total muscle. Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice (Animal context · Accessed 2026-09-30)

Source context — Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice: Preclinical cells and mice. Enzyme solutions are not bodily half-life measurements. One local muscle versus contralateral control is not whole-body human growth. Origin family Takayama 2022, DOI 10.1021/acsmedchemlett.1c00705.

More muscle beyond a plateau. A muscle-building commenter mentions mouse results but cannot find a human injection account. They describe no personal exposure, so their post supplies neither a positive result nor a nonresponse. New to peptides (muscle building) (Community discussion · Accessed 2026-09-30)

No established feeling to recognize. The community record supplies no human fullness diary, workout-pump pattern or consistent subjective effect. It cannot tell readers whether an immediate sensation, or feeling nothing, would predict later muscle change.

Source context — New to peptides (muscle building): One commenter, not a self-use report. No personal dose, route, timeline or adverse diagnosis. Relative timestamp shown as 2mo; earlier detail's July 11 2026 date not independently recoverable and not reused. No prevalence or global absence claim.

Human amount and frequency: unknown here. Neither the commenter nor the community record supplies personal human amounts or a dosing calendar. Mouse amounts remain separate below. New to peptides (muscle building) (Community discussion · Accessed 2026-09-30)

FLGR-242 amounts are a separate claim. The preserved comparison mentions 2.5–5 mg subcutaneously for FLGR-242, not MID-35. It supplies neither a MID-35 per-administration amount nor a daily total, and does not support converting between them.

2022: one locally treated muscle. A single 30 nmol intramuscular administration produced a treated mouse muscle weighing 133% of the opposite saline-treated muscle at day 28. That means roughly 33% heavier, not a 133% gain in a person's total muscle. Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice (Animal context · Accessed 2026-09-30)

2026: later muscle size is not peptide persistence. A separate mouse study used 2 nmol locally and followed muscle changes through day 84. The authors inferred an early direct effect lasting under seven days; they did not measure a human half-life or prove that intact peptide remained for twelve weeks. Myostatin Inhibitory D-Peptides Induce Skeletal Muscle Hypertrophy along with Alteration of Bioactive Sphingolipid Metabolism (Animal context · Accessed 2026-09-30)

Source context — New to peptides (muscle building): One commenter, not a self-use report. No personal dose, route, timeline or adverse diagnosis. Relative timestamp shown as 2mo; earlier detail's July 11 2026 date not independently recoverable and not reused. No prevalence or global absence claim.

Source context — Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice: Preclinical cells and mice. Enzyme solutions are not bodily half-life measurements. One local muscle versus contralateral control is not whole-body human growth. Origin family Takayama 2022, DOI 10.1021/acsmedchemlett.1c00705.

Source context — Myostatin Inhibitory D-Peptides Induce Skeletal Muscle Hypertrophy along with Alteration of Bioactive Sphingolipid Metabolism: Mouse outcome course and authors' inferred early action, not peptide concentration measurements or human duration/half-life. Source family Morito 2026 DOI 10.1021/acsptsci.6c00124.

Human onset: not described. These accounts supply no firsthand timeline from administration to a feeling, strength change or muscle gain, whether minutes, hours or days. New to peptides (muscle building) (Community discussion · Accessed 2026-09-30)

No human benefit or stopping timeline. The community record has no washout account: no description of how long a feeling lasted, whether gains persisted after stopping, or whether any change reversed. These are different questions from bodily half-life.

2026: later muscle size is not peptide persistence. A separate mouse study used 2 nmol locally and followed muscle changes through day 84. The authors inferred an early direct effect lasting under seven days; they did not measure a human half-life or prove that intact peptide remained for twelve weeks. Myostatin Inhibitory D-Peptides Induce Skeletal Muscle Hypertrophy along with Alteration of Bioactive Sphingolipid Metabolism (Animal context · Accessed 2026-09-30)

No human half-life measurement supplied. The discussion contains no measurement of how quickly MID-35 leaves a person's body. Later muscle size cannot supply that measurement. New to peptides (muscle building) (Community discussion · Accessed 2026-09-30)

Source context — New to peptides (muscle building): One commenter, not a self-use report. No personal dose, route, timeline or adverse diagnosis. Relative timestamp shown as 2mo; earlier detail's July 11 2026 date not independently recoverable and not reused. No prevalence or global absence claim.

Source context — Myostatin Inhibitory D-Peptides Induce Skeletal Muscle Hypertrophy along with Alteration of Bioactive Sphingolipid Metabolism: Mouse outcome course and authors' inferred early action, not peptide concentration measurements or human duration/half-life. Source family Morito 2026 DOI 10.1021/acsptsci.6c00124.

No documented human course in these accounts. The community record does not establish a repeat calendar or break length. Its contrast with FLGR-242 fortnightly talk is not a MID-35 schedule; neither is a vendor-style twelve-week block.

Comparison is different from stacking. The original community material discusses FLGR-242 alongside MID-35 rather than documenting combined use. It gives no MID-35 Wolverine-stack report. The anamorelin pairing comes from a mouse cancer-wasting experiment, not a gym user's stack diary. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model (Animal context · Accessed 2026-09-30)

Selectivity is unsettled. Cell assays affected related growth signals, with differing activin-A results. The cachexia experiment's anamorelin combination also increased tumour size; it cannot establish human combination safety, interactions, pregnancy safety or long-term tolerability. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model (Animal context · Accessed 2026-09-30)

Anamorelin combination: A mouse cancer-wasting experiment paired the compounds and also found increased tumour size with the combination. This cannot establish human combination benefit or safety. [animal]

Compared with FLGR-242, not stacked. [community]

Wolverine comparisons: The saved record contains no verified combined-use report linking this compound to that stack. [community]

Source context — Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model: Cancer-bearing mice, not bodybuilding, human interaction testing or a human stack. Single MID-35 arm did not improve survival. Origin family same 2022 cachexia paper across PMC and Europe PMC; mirrors share allowance.

Selectivity is unsettled. Cell assays affected related growth signals, with differing activin-A results. The cachexia experiment's anamorelin combination also increased tumour size; it cannot establish human combination safety, interactions, pregnancy safety or long-term tolerability. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model (Animal context · Accessed 2026-09-30)

Heart concerns are speculation in this account. The commenter worries about excessive heart-muscle growth but describes no exposure or diagnosis. This is speculation, not an observed adverse event. New to peptides (muscle building) (Community discussion · Accessed 2026-09-30)

Sport eligibility is a separate risk. WADA's 2026 list prohibits myostatin inhibitors at all times. MID-35 need not be individually named for the class concern to matter; these accounts supply no clearance interval. WADA 2026 Prohibited List (Official context · Accessed 2026-09-30)

Source context — Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model: Cancer-bearing mice, not bodybuilding, human interaction testing or a human stack. Single MID-35 arm did not improve survival. Origin family same 2022 cachexia paper across PMC and Europe PMC; mirrors share allowance.

Source context — New to peptides (muscle building): One commenter, not a self-use report. No personal dose, route, timeline or adverse diagnosis. Relative timestamp shown as 2mo; earlier detail's July 11 2026 date not independently recoverable and not reused. No prevalence or global absence claim.

Source context — WADA 2026 Prohibited List: Official sport category, not a safety assessment or named MID-35 detection/clearance window. S0 is residual for substances not addressed later; do not double-count it as a separate MID-35 finding.